Novel selective proline-based peptidomimetics for human cathepsin K inhibition

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Human cathepsin K (CatK) is a critical enzyme in bone matrix degradation and a promising therapeutic target for osteoporosis.
• The S2 subsite of CatK is small and shallow, with a preference for proline or hydroxyproline residues.

Purpose of the Study:

• To design and synthesize novel, rigid proline-based peptidomimetic inhibitors targeting human CatK.
• To achieve selective inhibition of CatK over other human cathepsins (B, L, and S).

Main Methods:

• Rigidification of the P2 leucine fragment in dipeptidyl-based inhibitors to create proline-based analogs.
• Synthesis of novel peptidomimetics incorporating trifluoromethylpyrazole and 4-methylproline substituents.
• In vitro enzymatic assays to determine CatK inhibition and selectivity against cathepsins B, L, and S.

Main Results:

• The newly designed proline-based inhibitors demonstrated selective inhibition of CatK.
• The most potent inhibitor exhibited high affinity for CatK (pK_i = 7.3, 50.1 nM).
• This lead compound showed no inhibitory activity against cathepsins B, L, and S, highlighting its specificity.

Conclusions:

• The development of rigid proline-based analogs represents a successful strategy for creating potent and selective CatK inhibitors.
• Novel substituents, trifluoromethylpyrazole and 4-methylproline, contribute to the enhanced affinity and selectivity of the inhibitors.
• These findings advance the development of targeted therapies for osteoporosis by providing novel CatK inhibitors.